Neuropathology Core

神经病理学核心

• 批准号: 10643933
• 负责人: THOMAS M WISNIEWSKI
• 金额: $ 23.17万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10643933
• 关键词: Acceleration; Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Animal Model; Autopsy; Biological Markers; Blood Vessels; Brain; Cell Line; Cell model; Clinical; Collaborations; Collection; Communities; Data; Dementia; Diagnosis; Diagnostic; Education and Outreach; Enrollment; Evaluation; Family; Health Professional; Heterogeneity; Image; Impaired cognition; International; Intervention; Measures; Methods; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Participant; Pathogenesis; Pathology; Patients; Procedures; Property; Proteomics; Protocols documentation; Reporting; Research; Research Personnel; Resources; Risk; Sampling; Source; Standardization; Syndrome; System; Technology; Therapeutic; Tissue Sample; Tissues; Training; Work; brain tissue; disease heterogeneity; induced pluripotent stem cell; innovation; laboratory facility; mild cognitive impairment; neuroimaging; neuropathology; new therapeutic target; next generation; normal aging; novel; novel diagnostics; novel therapeutic intervention; prevent; programs; psychosocial; repository; research clinical testing; therapeutically effective; tissue processing

ABSTRACT- NEUROPATHOLOGY CORE The Neuropathology (NP) Core provides for diagnostic neuropathological evaluations of: 1) patients and control subjects enrolled in the Clinical Core (CC), and 2) other clinically well documented patients with neurodegenerative disease. The NP Core aims to enhance understanding of the heterogeneity of AD/ADRD to develop better biomarkers and discover novel and effective therapeutic approaches that promote progress towards achieving the NAPA research implementation milestones. The protocols used by the NP Core will be state of the art and consistent with 21st century brain banking procedures. These will be essential to meet the increasingly sophisticated needs of the AD research community. We will emphasize delineating the presence of overlapping neurodegenerative syndromes. In this renewal, we will continue to emphasize the central theme of the NYU ADRC: elucidating the clinico-pathological substrates that underlie the transitions between normal aging, subjective cognitive decline (SCD), MCI, and dementia to help develop novel interventions that delay or prevent these transitions. The overall objectives of the NP Core of the NYULH ADRC are to provide staff, technical resources, laboratory facilities, and expertise to investigate the structural and molecular properties of the brains of both patients with ADRC and those of normal controls. Aims 1–3 of the NP core encompass the key neuropathology functions of the NP Core. Aims 4 and 5 will develop innovative neuropathological technologies. The emerging clinical evaluation system of ATN—which is proposed to underlie transitional stages between normal aging to SCD, SCD to MCI, and MCI to early dementia—needs to be correlated with comprehensive neuropathological measures that also reflect disease heterogeneity. In addition, while brain tissue is an essential resource, it cannot be developed into dynamic cellular models. Hence, the NP Core has launched a new induced pluripotent stem cell (iPSC) program, providing investigators with an easily replenished source of tissue to address key questions about the heterogeneous pathogenesis of AD/ADRC. Aims 6 and 7 focus on using NP Core resources to train the next generation of neuropathologists and translational neuroscientists conducting research on AD/ADRD, support their studies to develop novel therapeutic targets, and promote educational outreach about brain and biospecimen donation. The combination of these aims will help the NP Core to develop better biomarkers and to discover novel effective, therapeutic approaches; hence, accelerating progress towards achieving the NAPA research implementation milestones.

摘要--神经病理学核心 神经病理学(NP)核心提供以下诊断神经病理学评估：1)患者和对照 在临床核心(CC)中登记的受试者，以及2)其他有良好临床记录的患者 神经退行性疾病。NP核心旨在加强对AD/ADRD异质性的了解 开发更好的生物标记物，发现促进进步的新的有效治疗方法 朝着实现国家适应行动方案研究实施的里程碑迈进。NP核心使用的协议将 保持最先进的状态，并与21世纪的大脑银行程序保持一致。这些将是满足以下要求的关键 AD研究界日益复杂的需求。我们将重点描述 重叠的神经退行性综合征。在这次更新中，我们将继续强调以下中心主题 纽约大学ADRC：阐明正常人之间转换的临床病理基础 衰老、主观认知衰退(SCD)、轻度认知障碍和痴呆症，以帮助开发新的干预措施，延迟或 防止这些转变。NYULH ADRC的NP核心的总体目标是提供工作人员， 技术资源，实验室设备和专业知识，以研究结构和分子性质 ADRC患者和正常对照组的脑组织。NP核心的目标1-3包括 NP核心的关键神经病理功能。AIMS 4和5将开发创新的神经病理学 技术。新出现的ATN临床评估系统--建议作为过渡阶段的基础 从正常衰老到SCD，SCD到MCI，以及MCI到早期痴呆-需要关联 全面的神经病理测量，也反映了疾病的异质性。此外，当大脑 组织是一种必不可少的资源，它不能发展成动态的细胞模型。因此，NP核心具有 启动了一个新的诱导多能干细胞(IPSC)计划，为研究人员提供了一个容易补充的 组织来源，以解决AD/ADRC异质性发病机制的关键问题。目标6和7 专注于利用NP核心资源培训下一代神经病理学家和翻译 神经科学家对AD/ADRD进行研究，支持他们开发新的治疗靶点的研究， 并促进关于脑部和生物制品捐赠的教育宣传。这些目标的结合将 帮助NP Core开发更好的生物标志物，并发现新的有效的治疗方法；因此， 加快实现国家适应行动方案研究执行里程碑的进展。